media – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Medical Philippines

Organiser：Philippine Medical Association, Fireworks Exhibitions Singapore Time：August 13-15, 2025 Address：Seashell Ln, Pasay, 1300 Metro Manila, Philippines Exhibition hall：SMX Convention Center Manila Product range: Medical Devices & Equipment: Medical Assistive Devices, Diagnostic Equipment, Monitoring Equipment, Therapeutic Equipment, Laboratory & Analytical Equipment, Surgical Special Equipment, Sterilization Equipment, Traction & Orthopedic Devices, Rehabilitation & Physical Therapy Equipment, Medical Vehicles, Beds, Tables, Emergency & Rescue Equipment, Surgical Equipment, Diagnostic Supplies & Equipment, Analysis & Control, Monitoring Devices, Surgical Instruments, Preventive Medicine Equipment, Ophthalmic Instruments & Equipment, ENT Equipment, Dental Supplies & Equipment, Radiological Medical Equipment, Medical Reagents & Equipment, Prostheses & Rehabilitation Equipment, Medical Healthcare Products & Equipment, Medical Assistive Devices, Diagnostic Equipment, Therapeutic Equipment, Laboratory & Analytical Equipment, etc. Medical Institutions & Laboratory Technology Equipment: Laboratory Instruments & Equipment, Laboratory Furniture, Laboratory Automation & Accessories, Optical Instruments & Equipment, Medical Laboratory Analysis & Diagnostic Instruments, Biopharmaceutical Instruments, Cellular Biology Instruments, Biotechnology Equipment, ...
- Source: drugdu
- 30
- November 21, 2024
Commercial raw liquid and formulation workshop of Altruist Biologics ADC has been officially put into operation

On November 15, 2024, Altruist Biologicstech, a leading domestic biopharmaceutical CDMO company, announced that its antibody conjugated drug (ADC) raw liquid and formulation production workshop (M3) located at its Hangzhou production base has officially started production! Becoming one of the few companies in China that can provide one-stop services from antibody and antibody conjugate drug stock solutions to formulations. This powerful production capacity will be able to meet the growing demand for ADC drugs in the market, accelerate the process of partner product launch, and enhance competitiveness. On that day, Altruist Biologicstech Hangzhou Base welcomed a visiting delegation composed of outstanding founders and executives from the domestic biopharmaceutical industry, who visited the ADC commercial raw material and preparation workshop, as well as four 20000 liter antibody raw material factories and preparation factories. The delegation expressed high interest and appreciation for the design layout, advanced hardware facilities, and automated production lines ...
- Source: drugdu
- 41
- November 20, 2024
Barco showcases new products at CCR2024, adding momentum to precision medicine

The 31st Radiology Academic Conference of the Chinese Medical Association (CCR2024) was held at the Shanghai World Expo Center from November 14th to 17th. Barco showcased its new Coronis OneLook 32MP multimodal diagnostic imaging display, integrated reading center, and multiple radiology displays at the booth, bringing cutting-edge technology and outstanding products to the Chinese precision medicine market with updated and more comprehensive solutions. New product One Look 32MP unveiled, showcasing higher standards in the medical display field The display is a bridge connecting radiologists and medical imaging, and its performance directly affects the accuracy of doctors’ capture, interpretation, and diagnosis of image details. At this conference, Barco unveiled its new Coronis OneLook 32MP multimodal fusion display, bringing more refined solutions to the Chinese medical market. The Coronis OneLook 32MP multimodal fusion display is Barco’s industry-leading medical display solution, featuring a 32MP ultra high definition resolution and a 33 inch large ...
- Source: drugdu
- 41
- November 20, 2024
【EXPERT Q&A】How to determine the clinical evaluation path of medical devices?

Drugdu.com expert’s response: The clinical evaluation pathway for medical devices is a crucial process for assessing their safety and effectiveness, determining their suitability for market release and clinical use. Below are the general steps and considerations for determining the clinical evaluation pathway for medical devices: Ⅰ. General Steps Clarify Product Characteristics and Scope of Application: Understand the basic principles, structural composition, manufacturing materials, and intended use of the medical device. First, confirm the scope of application of the product to facilitate targeted clinical evaluation. Assess Clinical Risks and Existing Clinical Data: Analyze potential adverse events or risks associated with the product during use. Evaluate whether sufficient clinical data exist to support the safety and effectiveness of the product. Select Clinical Evaluation Pathway: Based on product characteristics, clinical risks, and existing clinical data, select the most suitable clinical evaluation pathway. Ⅱ. Considerations Inclusion in the “Catalogue of Medical Devices Exempt from ...
- Source: drugdu
- 27
- November 20, 2024
Prepayment system can speed up hospital payments to suppliers

Recently, the National Medical Insurance Administration and the Ministry of Finance jointly issued the “Notice on Prepayment of Medical Insurance Funds” (hereinafter referred to as the “Notice”) to further standardize the prepayment system and clarify the scope of use and allocation of prepayments. conditions and expenditure standards, and standardizes the process management, accounting and fund supervision of advance payments. The prepayment system effectively relieves the financial pressure on medical institutions. By allocating medical insurance funds in advance, the prepayment system significantly reduces the cash flow pressure of medical institutions waiting for reimbursement settlement, helps hospitals better manage operating funds, and ensures the continuity and stability of medical services. Prepayments can be used to transfer funds for medical expenses such as the purchase of drugs and medical consumables, allowing hospitals to pay suppliers faster, reducing the pressure on financing in the medical and pharmaceutical industry, and improving the cash flow level ...
- Source: drugdu
- 27
- November 20, 2024
Atropine that “does not adapt to local conditions”

Pharmaceutical companies around the world have high hopes for atropine. After all, the demand for myopia prevention is very clear and huge. The most critical thing is the extremely large demand group. According to Eyenovia’s estimates, myopia is estimated to affect about 25 million children in the United States, of which up to 5 million are considered to be at high risk of progressive myopia. The same is true in China. According to Guosheng Securities’ estimate, the size of the myopia group of children and young people aged 6-16 is about 78 million. For this group of people, there are currently two major problems: some groups have no effective means of delay, and those with means of delay need solutions with better compliance and lower costs. At present, among the main measures to control and delay myopia, wearing frame glasses is convenient but has poor effects; optical correction (wearing orthokeratology ...
- Source: drugdu
- 31
- November 20, 2024
Refusal to adjust prices, a number of pharmaceutical companies “out”

On November 18, at the 44th China Pharmaceutical Industry Development Summit Forum, Geng Hongwu, executive deputy director of the Medical and Health Research Center of the Tsinghua University Association of Senior Scientists, pointed out that the basic ideas of my country’s medical insurance drug price management at this stage mainly include: management scope, quality-price matching, reasonable price difference, medical insurance guidance, strict supervision, etc. “Exerting the effectiveness of drug price governance” is one of the key tasks of the National Medical Insurance Administration this year. That is, to promote special governance of online drug prices, explore new mechanisms for drug price formation, and increase the disclosure of price procurement credit evaluation. Recently, the Shanxi Provincial Drug and Equipment Centralized Bidding and Procurement Center issued the “Notice on the Adjustment and Disposal of the Centralized Procurement Prices of Amoxicillin and Other Drugs of the Guangdong Alliance”. The relevant companies of 20 ...
- Source: drugdu
- 29
- November 20, 2024
Celltrion expands European market, acquires iQone Healthcare for 30 billion

On Friday, South Korean biosimilar giant Celltrion said it had completed the acquisition of iQone Healthcare Switzerland for approximately 30 billion won (about 155 million yuan) as part of its European expansion strategy. After the acquisition, iQone Healthcare Switzerland will become a wholly-owned subsidiary of Celltrion Healthcare Hungary Kft. The transaction will also provide Celltrion with the opportunity to obtain authorizations, further enhancing its pipeline of innovative therapies. In 2022, iQone’s annual revenue was 18.9 billion won (about 18.9 million US dollars), and sales increased by 57% to 29.6 billion won in 2023. Celltrion said the acquisition will further accelerate the expansion of its prescription drug business in Switzerland. According to IQVIA data, sales performance in the country remains strong, with the Ramsima series (IV and SC) accounting for 61% of the market share in the second quarter of this year. The company noted that its follow-up products are expected ...
- Source: drugdu
- 30
- November 20, 2024
Pumis announces equity acquisition agreement with BioNTech

According to the terms of the agreement, BioNTech will acquire 100% of Pumis’ issued share capital for a prepayment of $800 million (approximately RMB 5.781 billion) (subject to customary adjustment of the acquisition price), primarily in cash and a portion of American Depositary Shares (ADS). In addition, BioNTech will pay an additional milestone payment of up to $150 million (approximately RMB 1.084 billion) when Pumis meets the milestone conditions agreed upon by both parties. The transaction is expected to be completed in the first quarter of 2025, subject to customary delivery conditions and regulatory approvals. After the completion of this transaction, BioNTech will acquire full rights to the Pumis candidate drug pipeline and its bispecific antibody drug development platform, further expanding its business scope in China; Pumis Zhuhai will serve as the BioNTech China R&D center to conduct related R&D research; The Pumis Nantong production base, which meets international standards, ...
- Source: drugdu
- 40
- November 19, 2024
WuXi AppTec’s Couvet Site Receives EcoVadis 2024 Silver Medal Rating

Couvet, Switzerland – November 14, 2024 – WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, is proud to announce that its facility in Couvet, Switzerland, has received a silver medal in the 2024 business sustainability ratings by EcoVadis, a leading business sustainability rating provider. This recognition highlights WuXi AppTec’s steadfast commitment to integrating Environmental, Social, and Governance (ESG) priorities into its strategy and operations. EcoVadis provides benchmarks for rated companies in their industry to drive global supply chain sustainability and encourage industry-wide competence to achieve better global practice and continuous improvement. The ratings assess corporate performance across four core areas: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. With an impressive score, WuXi AppTec’s Couvet site ranks in the top 9% of all rated companies, showcasing its commitment to sustainable business practices. ...
- Source: drugdu
- 37
- November 19, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.